|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||10 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||602.63 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Lymecycline is a tetracycline broad-spectrum antibiotic. It is approximately 5,000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by an active transport process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.
The greater absorption of lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base and, in its action, to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all physiological pH values.
Lymecycline was released into the pharmaceutical market in 1963.
Lymecycline, like other tetracyclines, is used to treat a range of infections. Its better absorption profile makes it preferable to tetracycline for moderately severe acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.
Lymecycline's side effects can include rash, headache, diarrhoea, nausea, vomiting, dermatitis, inflammation of the liver, hypersensitive reactions, and visual disturbances. When taken for a long period of time, it can cause reflux oesophagitis. Recently, the family of tetracycline antibiotics has been associated with thyroid dysfunction in youth.
- New Zealand Datasheet Archived 2006-03-03 at the Wayback Machine August 2003
- British National Formulary 45 March 2003
- Wang P. "Side effects of Tetralysal". Retrieved 23 March 2011.
- Pollock AJ, Seibert T, Allen DB (June 2016). "Severe and Persistent Thyroid Dysfunction Associated with Tetracycline-Antibiotic Treatment in Youth". The Journal of Pediatrics. 173: 232–4. doi:10.1016/j.jpeds.2016.03.034. PMC 4884496. PMID 27059913.